26/08/2026
The impact of PEPFAR HIV funding cuts.
Source: AVAC
Significant challenges persist in the wake of cuts to PEPFAR programs, as the ripple effects continue to be felt across the field and organizations grapple with how to maintain services with fewer resources.
At the start of the conference, amfAR released a report detailing the results from their recent PEPFAR Pulse study. The study provides the first concrete evidence and key details on the impact of PEPFAR cuts: surveying 166 organizations in 46 countries, they found that nearly 2,000 service sites had been forced to shutter.
The results from the study were significant: almost no organizations were able to fill the funding gap with other donors. Services for key populations (KPs) were “decimated”: 73% of implementing partners stopped at least one KP service and 67% stopped outreach services.
HIV prevention services overall took a huge hit: PEPFAR expenditures for condoms and lubricants were almost completely cut, while non-biomedical HIV prevention and VMMC expenditures were cut in half and PrEP expenditures were reduced by 38%. Expenditures for associated services such as violence prevention and response were also cut by two-thirds.
As a result almost half of respondents reporting that they had halted key prevention activities such as condom or PrEP distribution. Two-thirds reported interruption of PMTCT and nearly one in four stopped providing prevention of mother-to-child transmission services entirely. As outlined in amfAR’s accompanying JIAS article analyzing service delivery data from PEPFAR-supported facilities, these cuts have resulted in drastic reductions in the number of people served.
Additionally, the release of UNAIDS’ United to End AIDS special report and a companion KFF-UNAIDS analysis shared results on the global picture of the AIDS epidemic and donor funding landscape.
The report shows HIV financing entering one of its most precarious periods in decades, with international assistance declining 18% between 2024 and 2025. Donor government funding fell by $2.1 billion in 2025—the largest annual decline since global HIV funding began scaling up—and epidemiological progress has stalled, with new HIV infections remaining essentially unchanged for the third consecutive year.
Taken together, these findings underscore the broader challenges facing the field in effectively translating scientific progress into the impact needed to end AIDS as a public health threat by 2030.